1.0JNNP bloghttps://blogs.bmj.com/jnnpDr José Manuel Matamala, JNNP web editor.https://blogs.bmj.com/jnnp/author/jmatamalacapponi/rich600338<blockquote class="wp-embedded-content" data-secret="tI3jRQQ8LW"><a href="https://blogs.bmj.com/jnnp/2019/12/12/improving-clinical-trials-in-als/">Improving clinical trials in ALS</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://blogs.bmj.com/jnnp/2019/12/12/improving-clinical-trials-in-als/embed/#?secret=tI3jRQQ8LW" width="600" height="338" title="“Improving clinical trials in ALS” — JNNP blog" data-secret="tI3jRQQ8LW" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript"> /* <![CDATA[ */ /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://blogs.bmj.com/jnnp/wp-includes/js/wp-embed.min.js /* ]]> */ </script>   The clinical trial design is extremely complex in neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS). The clinical and pathological heterogeneity of ALS has made therapeutic targets difficult to identify, increasing the variability in endpoints. Nowadays, the most effective interventions in ALS are multidisciplinary clinics and non-invasive ventilation, which can significantly improve quality of [...]Read More...https://blogs.bmj.com/jnnp/files/2019/12/Fig-1.1.jpg